Huntington's disease (HD) is an autosomal-dominant neurodegenerative disease caused by an expanded polyglutamine tract in the ubiquitously-expressed huntingtin protein. Clinically, HD is characterized by motor, cognitive and psychiatric deficits.
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant, progressive and fatal neurodegenerative disorder caused by an expanded (>35-38) polyglutamine (polyQ) tract in the ubiquitously-expressed huntingtin protein. Despite widespread expression of mutant huntingtin (mhtt), selective dysfunction and degeneration of specific neuronal subpopulations characterize HD and lead to motor, cognitive and psychiatric abnormalities. Among these neuronal subtypes, the medium spiny neurons (MSNs) of the striatum demonstrate the most striking vulnerability. As MSNs comprise 95% of total neurons in this nucleus (1) , striatal atrophy constitutes a neuropathological hallmark of HD despite the relative sparing of other striatal cell types (2) . Notably, however, early and substantial cortical degeneration is also observed in HD patients (3) (4) (5) (6) (7) , leading to the hypothesis that changes in the cortex may be primarily responsible for dysfunction and death of MSNs.
In HD, the abundant connections between the cortex and striatum serve to link the degenerative processes in these areas and make the delineation of their relative contributions to pathogenesis extremely challenging (8, 9) . The striatum receives massive glutamatergic innervation (10) and neurotrophic support (11) from the cortex.
Abnormalities in either excitotoxic mechanisms and/or trophism, particularly from a decrease in cortical brain derived neurotrophic factor (BDNF), may contribute to striatal pathology in HD (12) (13) (14) (15) (16) .
Possibly related to these corticostriatal mechanisms is the transcriptional dysregulation which is likely a critical, early event in HD pathogenesis. Numerous studies have described disrupted transcriptional pathways and altered striatal gene expression profiles in both HD patients and models (17) . Microarray studies show that levels of approximately 2% of striatal transcripts are altered and that most of these are decreased. These studies also show that the pattern of transcriptional dysregulation observed in human brain is quite accurately reproduced across multiple mouse HD models (18) (19) (20) (21) .
The down-regulation of several specific transcripts, e.g.
preproenkephalin (PPE) (22,23), dopamine and cyclic AMP-regulated phosphoprotein, 32 kDa (DARPP-32) (24) and neurotransmitter and neuropeptide receptors, including the D1 and D2 dopamine receptors, the adenosine A2A receptor, and the CB1 cannabanoid receptor (25) (26) (27) (28) (29) , has been particularly well-studied and quantitated. Several mechanisms have been proposed to explain the reductions in steady-state levels of striatal mRNAs in HD. Cell-autonomous mechanisms include altered regulation of histone modifications, abnormal interactions between mhtt and transcription factors and/or directly with DNA, and transcriptional repression due to loss of wild-type huntingtin function (17, (30) (31) (32) .
Decreased cortical neurotrophic support is a particularly relevant non-cell-autonomous potential mechanism leading to transcriptional dysregulation as suggested by the similarities of striatal microarray profiles of forebrain-specific BDNF-knockout-mice and human HD (16) .
We sought to determine the extent of cell-autonomous striatal pathology and transcriptional dysregulation in a murine model of HD. To this end, we created a line of transgenic mice that, within the forebrain, selectively expresses a cDNA encoding the Nterminal 171 amino acids of human huntingtin with a 98Q polyglutamine tract expansion (N171-98Q) in the striatal MSNs. Regulatory components of genomic elements from DARPP-32 (i.e. "D9") (33) were used to target expression of the pathogenic huntingtin fragment. These mice demonstrate MSN nuclear inclusion formation, a motor phenotype, and striatal gene expression changes similar to those seen in pan-cellular and pan-neuronal HD models. These data provide the first unambiguous evidence of in vivo cell-autonomous MSN transcriptional dysregulation and the development of motor abnormalities in the absence of neocortical transgene expression in an HD model.
RESULTS

DARPP-32 elements target expression of mhtt to the MSNs, resulting in inclusion formation
Genomic fragments from the mouse DARPP-32 gene, hereafter referred to as "D9", are known to direct transgene expression to the MSNs of the striatum (33) . In that study, D9 was also noted to direct expression to the choroid plexus, olfactory tubercle, piriform cortex, and in an insertion-site dependent manner, Purkinje cells. Importantly, these are all areas of endogenous DARPP-32 expression. The identical genomic elements were used to direct expression of a cDNA encoding the N-terminal 171 amino acids of the human huntingtin protein with an expanded polyglutamine tract length of 98 (D9-N171-98Q; Fig. 1 ). Western blot analysis of regionally dissected brain tissue from the highest expressing line, DE5, demonstrates high transgene expression in the striatum and cerebellum, and barely detectable expression in the neocortex ( Fig. 2A) .
The primary goal of the current study is to compare the DE5 line to models ubiquitously expressing mhtt. The comparison to the well-characterized PrP-N171-82Q
is particularly relevant, as in this model, the mouse prion promoter directs pan-neuronal and possibly glial expression of an identical mhtt fragment with an 82Q expansion 5 by guest on http://hmg.oxfordjournals.org/ Downloaded from (34, 35) . These mice die with severe motor and transcriptional abnormalities by six months of age (19, 34) . It is therefore important to note that striatal levels of transgenic protein in DE5 are higher than in PrP-N171-82Q mice at all ages analyzed (Fig 2B) , and a smaller transgene band is evident in both DE5 and PrP-171-82Q, likely an in vivo cleavage product (34) . Even more important is the fact that no molecular or behavioral abnormalities are present in mice ubiquitously expressing N171-18Q (non-expanded) (19,34).
Immunocytochemistry with EM48, an antibody preferentially recognizing aggregated huntingtin (36) , shows diffuse nuclear staining in DE5 striatal neurons as early as 2 months of age (Fig. 3A) . Inclusion bodies are evident by 6 months of age and increase progressively in size and number so that by 22 months, large inclusions are present in virtually every EM48-positive cell in the striatum while cortical expression, particularly in pyramidal projection neurons, remains undetectable ( Fig. 3B-E) . Of note, inclusions in Purkinje cells are first detected at 8.5 months of age and are less numerous than in the striatum at 22 months of age (Fig. 3F) . Thus, within the forebrain, D9-N171-98Q directs expression of high levels of mutant huntingtin in the MSNs of the striatum in the absence of neocortical expression and in vivo cell-autonomous mutant huntingtin aggregation and inclusion formation occurs in MSNs.
Forebrain weight is reduced in D9-N171-98Q mice but striatal cellular morphology appears normal
To further characterize the neuropathology of the DE5 mice, we analyzed gross and cellular striatal morphology. DE5 forebrain weight is reduced relative to non- Fig. 4A-D, F-I ). MSN cellular morphology appears normal ( Fig. 4E and J). Stereological analysis is in progress to determine if more subtle changes in striatal volume or cellularity are evident, and to determine the cause of the decrease in ventricular size. Anti-glial fibrillary acidic protein (GFAP) staining does not reveal reactive gliosis in the striatum (Fig. 5) .
D9-N171-98Q mice demonstrate a failure to gain weight, deficit in rotarod performance and hypoactivity.
Body mass, performance on an accelerating rotarod apparatus and locomotor activity were measured every two months in both male and female D9-N171-98Q (DE5) cohorts up to 16 months of age. DE5 mice of both sexes failed to gain weight beginning at 12 months of age (Fig. 6A) . The longitudinal analysis revealed a deficit in rotarod performance in DE5 females relative to their non-transgenic littermates that progressively worsened between 10 and 16 months of age (Fig. 6B) . No rotarod deficit was detected in the male cohort and no differences in locomotor activity were observed in either sex (data not shown). Although sex-based differences in phenotype have been reported in HD mouse models and in the human disease (37) (38) (39) , it was somewhat surprising that the longitudinally-tested male cohort failed to demonstrate any significant deficits in rotarod performance. We therefore tested a second larger cohort of males at a single age of 16 months. The observed deficit in this second cohort suggests that motor impairment is not limited to females (Fig. 6C) , although sex differences may exist and require further investigation, particularly as to the effects of learning. The second cohort of DE5 male mice also demonstrated hypoactivity in the locomotor apparatus that was most pronounced during the first 5 minutes, suggesting a decrease in either exploratory behavior or anxiety (Fig. 6D) . These data may explain the absence of hypoactivity in mice from the longitudinal studies, which were habituated to the apparatus beginning at two months of age. Thus, in the DE5 mice, there is a late onset phenotype characterized by impaired performance on the rotarod, hypoactivity and failure to gain weight.
Gene expression analysis reveals cell-autonomous reductions in striatal mRNA levels
As noted above, an early molecular hallmark in human HD and in its mouse models is transcriptional dysregulation in MSNs. Quantitative RT-PCR on striatal mRNA was utilized to measure levels of numerous transcripts in DE5 mice, chosen from amongst those frequently found to be abnormal in other HD mouse models and/or relevant to cortical regulation of striatal function. The earliest significant decreases in mRNA levels are observed in preproenkephalin (PPE, p=0.003) and endogenous DARPP-32 (p=0.046) at 8.5 months (data not shown). Although a trend is evident at 4.5 months, the differences at that age are not statistically significant. By 13. (Fig. 7) . mRNA levels of the NMDA receptor subunits NR2A and NR2B are unchanged whereas NR1 mRNA levels are slightly decreased (p=0.035). Striatal mRNA levels of calbindin-28K (Calb1) are also unchanged. Importantly, BDNF mRNA levels in the cortex, and those of its main receptor, trkB, in the striatum, are equal in DE5 mice and controls ( Fig. 7 and 8A ). Transgene mRNA levels are also relatively decreased from 4.5 to 13.5 months in a pattern that mirrors the decrease in endogenous DARPP-32 levels
As D9 is derived from DARPP-32, this is an anticipated finding, but importantly, indicates that the regulatory elements that confer cell-specificity also confer down-regulation by mhtt. Finally, analysis of cerebellar mRNA levels demonstrates a decrease in calbindin-28K mRNA (p=0.040) representing a contrast to the lack of change observed in the striatum. The apparent decrease in DARPP-32 levels did not achieve significance (p=0.065) (Fig. 8C) . In summary, select and region-specific changes in MSN mRNA levels occur in the striatum in D9-N171-98Q mice.
Transgenic expression of striatal DARPP-32 does not cause motor, transcriptional, or morphologic abnormalities
In DE5 mice, expression of transgenic DARPP-32 protein from D9, as detected by an increase in total DARPP-32 levels, is present up to 3 months of age in striatum ( Fig. 9B) and in cerebellum at all ages analyzed (data not shown). Analysis of striatal DARPP-32 protein expression in DE5 mice was performed on several groups of young mice from 3 weeks to 3 months of age and results varied from zero to a 70% increase in DARPP-32 protein levels in DE5 relative to non-transgenic littermates. Based on these data, controls in all studies include non-transgenic littermates, as presented above, and in addition, we studied a second D9 transgenic mouse line, F6, with comparable striatal DARPP-32 expression (Fig. 9 ). This latter line was developed in an attempt to create a full-length model similar to D9-N171-98Q, in which D9 was used to direct expression of a cDNA encoding full-length human huntingtin with an expanded polyglutamine tract of 98 downstream of the IRES (D9-FLhtt-98Q). In the highest-expressing line, F6, striatal huntingtin expression was only 15% of the endogenous level (data not shown). Despite the low expression of transgenic huntingtin, we longitudinally followed cohorts in the same experimental paradigms as for DE5. F6 mice display normal brain morphology without a decrease in ventricular size (Fig. 9D ) and do not develop transcriptional abnormalities (Fig. 9E) , nor do they demonstrate any motor deficits up to 18 months of age in rotarod testing (non-transgenic: 91.6±10.0 sec, F6: 94.4±8.0 sec; average fall latency ±SEM; p=0.829, two-way repeated measures ANOVA). Immunostaining for huntingtin in F6 was undetectable (data not shown). Thus, transgenic huntingtin expression in F6 is too low to draw conclusions about the cell-autonomous effects of fulllength mhtt. Importantly, however, as striatal DARPP-32 expression is comparable to DE5 ( Fig. 9B-C) , a lack of phenotype in F6 allows for the exclusion of effects of transient striatal DARPP-32 over-expression. D9-N171-98Q mice exhibit a motor phenotype characterized by impaired rotarod performance and hypoactivity, both features common to many pan-neuronal HD mouse models. However, relative to the PrP-N171-82Q mouse, the D9-N171-98Q mouse exhibits a more protracted disease course and lacks several other reported behavioral abnormalities (34) . In particular, the PrP-N171-82Q mouse also displays tremors, an abnormal gait and frequent hindlimb clasping. Furthermore, deficits in rotarod performance are evident by 3 months of age and premature death occurs around 6 months of age. Thus, despite higher striatal expression and greater polyQ length, the D9-N171-98Q mouse only recapitulates some of the features of its most comparable pan-neuronal model, the PrP-N171-82Q mouse. Possible contributors to these differences in phenotype and its severity certainly include the presence of neocortical expression in PrP mice, as well as systemic abnormalities and background strain.
In several HD models, contributions to motor abnormalities from Purkinje cell dysfunction cannot be ruled out, but motor dysfunction is notably present in an HD mouse model lacking cerebellar transgene expression (47). Hindlimb clasping, present in several mouse HD models and in naturally-occurring cerebellar-specific mutant mice (41, 48, 49 ) is absent in D9-N171-98Q suggesting that this abnormality may include cortical dysfunction when originating from the forebrain. Finally, the D9-N171-98Q phenotype may be moderated by background strain. In the YAC128 mouse, the phenotype is less severe on a C57BL/6 background (50).
In general, D9-N171-98Q mice appear healthy, with normal breeding and life span, but there is a failure to gain weight followed by a small weight loss after 12 months Gene expression changes in striatal MSNs represent an early marker of neuronal dysfunction in HD, although the causal relationship to motor abnormalities is unknown.
The striatal microarray profile of the aforementioned forebrain-specific BDNF-knockoutmice (Emx-BDNF KO ) has been shown to be statistically more similar to human HD than that of several mouse HD models (16) . Striatal BDNF is critical for the maturation and maintenance of MSNs in vitro and in vivo (15, (54) (55) (56) . Wild-type, but not mutant, huntingtin promotes the transcription and vesicular transport of BDNF (13, 14, 31) , and BDNF protein is reduced in the cortex and striatum of HD patients and mouse models (13, (57) (58) (59) (60) . The primary striatal receptor for BDNF, trkB, may also be decreased in the presence of mhtt, further compromising BDNF-derived trophic support (58,61). Our In addition to offering mechanistic insights into a number of the molecular abnormalities observed in HD, our findings have important therapeutic implications. The ability to reverse neuropathology and motor dysfunction in an HD mouse model by blocking expression of mhtt (47) predicts potential efficacy of therapies targeting mhtt expression, e.g. intrabodies and RNA interference (63, 64) . Our demonstration of cell-autonomous MSN dysfunction further suggests that delivery of these therapies directly to the striatum may be sufficient to reverse key molecular abnormalities.
MATERIALS AND METHODS
Vector Design
A huntingtin cDNA encoding the first 171 amino acids with a CAG repeat length of 98 was removed from the plasmid pC3HD NXQ150 GFP (provided by Marcy MacDonald, Finally, a NotI to SalI fragment was excised from pIresHTstpBGHpA and inserted into D9 in place of the IRES and lacZ marker gene (33) . The linearized 11.7Kb transgenic vector was excised from D9 with PacI.
Transgenesis and Genotyping
The 11.7Kb D9-N171-98Q fragment was separated on 0.9% agarose gel, purified by 
Behavioral Analysis
Motor performance in male and female cohorts was assessed using a Rotamex Rotarod (Columbus Instruments) beginning at two months of age and continuing every other month up to 16 months of age. In a second male cohort, the first test was performed on naïve animals at 16 months of age. The first test consisted of three trials per day for four days (12 trials total). A trial involved placing a mouse on a slowly rotating rod that began at 8 rpm and increased 1 rpm every 8 seconds until the mouse fell off the rod or gripped the rod and rotated around with it. Mice received an hour of rest between trials.
In subsequent months, only 3 days of testing were performed (9 total trials). For all testing periods, only the last 6 trials were used, with the initial trials serving as training.
Data were analyzed by two-way repeated measures ANOVA (SigmaStat software). For the animals tested only at 16 months, the initial velocity of the rod was set to 4 rpm and 12 trials were performed over 4 days. All 12 trials were analyzed by two-way repeated measures ANOVA.
Locomotor activity level was measured as previously described (71). Briefly, animals were placed in one of eight identical transparent Plexiglas boxes equipped with MicroMax Animal Activity Monitors (Accuscan Instruments, Inc.) for 30 minutes. The monitors use infrared light emitters and detectors to detect animal presence. Total activity is measured as the total number of photo beam breaks over the allotted time.
Testing was performed on the same animals that underwent rotarod testing. A Student's t-test was used to compare activity levels of transgenic and non-transgenic animals at each time bin and for total activity and statistical significance was achieved at p<0.05.
Histology
Immunocytochemistry was performed as previously described (33) . Briefly, brains were fixed by transcardial perfusion with 4% paraformaldehyde in PBS followed by overnight immersion fixation in the same fixative and then stored in PBS at 4 o C. Brains were sectioned coronally on a vibratome (Leica Microsystems, Wetzlar, Germany) at 40µm.
The following primary antibodies were used for immunohistochemistry: rabbit polyclonal EM48 ( 
